Bajaj Electricals Q4 profit before tax jumps 191% to Rs 71 crore; consumer products EBIT surges 138%
Bajaj Electricals Ltd has posted a robust set of results for the quarter ended March 31, 2025, with profit before tax surging 191% year-on-year to ₹71 crore, supported by improved gross margins and strong performance in the Consumer Products segment.
The company's revenue from operations rose to ₹1,265 crore, up 6.5% from ₹1,188 crore in Q4FY24. The Consumer Products segment delivered ₹994 crore in revenue (up 8.4% YoY) and reported an EBIT of ₹39 crore, up from ₹16 crore in the same quarter last year—marking a 138% increase.
The Lighting Solutions segment remained flat with ₹271 crore in revenue, while EBIT stood at ₹21 crore, down from ₹23 crore a year earlier. However, the EBIT margin for this segment improved to 7.8%, driven by better gross margins.
For the fiscal year ending March 31, 2024, the company generated positive cash flow of ₹87 crore from operations and reported cash and investments of ₹509 crore.
Dividend declared at ₹3 per share
In line with its Dividend Distribution Policy, the Board of Directors has recommended a dividend of ₹3.00 per equity share (150% of face value of ₹2) for the financial year ended March 31, 2025. If approved at the company's 86th Annual General Meeting (AGM), the dividend will be credited or dispatched on or before August 11, 2025.
The record date for dividend eligibility is set as Friday, July 18, 2025, for shareholders holding shares in both physical and dematerialised form.
Leadership update and outlook
Mr. Shekhar Bajaj, Chairman of Bajaj Electricals, announced the appointment of Mr. Sanjay Sachdeva as the new Managing Director and CEO. Mr. Sachdeva, an alumnus of IIT Delhi and IIM Calcutta, joins from Unilever and brings extensive leadership experience across global markets.
Commenting on the company's outlook, Mr. Bajaj said, 'We will continue our investments in our brand and products and other initiatives which will yield strong results going forward.' He also expressed optimism regarding the macroeconomic environment, noting that recent RBI rate cuts and controlled inflation could boost consumer demand in the coming quarters.
News desk at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), held its Combined General Meeting (the 'General Meeting'). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Viaskin and EPIT are trademarks of DBV Technologies. Investor Contact Katie MatthewsDBV Media ContactAngela Marcucci DBV Attachment PDF VersionFehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
5 hours ago
- Yahoo
ONWARD Medical Announces Results of its Annual General Meeting of Shareholders
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Shareholders approve all proposed resolutions EINDHOVEN, The Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that that all proposed resolutions at its Annual General Meeting of Shareholders (AGM) were duly passed. The meeting was held this afternoon in Amsterdam, the Netherlands at 4:00PM CET. Full details of the resolutions approved during the AGM can be found on the Company's Investor Relations website. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company's ARC-EX System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI). Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). To learn more about ONWARD Medical's commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform. For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Disclaimer Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited. ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use.
Yahoo
6 hours ago
- Yahoo
Antin Infrastructure Partners SA: 2025 Annual Shareholder Meeting All Resolutions Are Adopted
Disclosure in accordance with the AMF recommendations PARIS & LONDON & NEW YORK, June 11, 2025--(BUSINESS WIRE)--Regulatory News: Antin Infrastructure Partners SA (Paris:ANTIN) held its Annual Shareholder Meeting today in Paris, under the chairmanship of Alain Rauscher, Chairman of the Board of Directors and Chief Executive Officer. The shareholders, who represented 97.50% of voting rights, approved all the resolutions presented, and in particular: approved the statutory and consolidated financial statements for 2024 decided on the distribution of an amount of €0.71 per share. Given the interim payment of €0.34 per share made on 14 November 2024, the balance of the distribution, i.e., €0.37 per share, will be paid on 18 June 2025 (ex-date: 16 June 2025) renewed, for a period of three years, the terms of office of Lynne Shamwana and Dagmar Valcarcel. The Board of Directors remains comprised of six members, three of whom are independent, and the composition of its Committees remains unchanged approved the 2025 compensation policies for the corporate officers, as well as the compensation paid or awarded for 2024 equipped the Board of Directors with a set of financial authorisations, giving it a degree of flexibility to initiate securities within a strictly defined framework The Board of Directors met after the Annual Shareholder Meeting and decided in particular to continue the liquidity agreement with BNP Paribas Arbitrage. Alain Rauscher invited shareholders to the next Annual Shareholder Meeting that will take place on 10 June 2026. The results of the votes are available on the website section "Shareholder Meetings". About Antin Infrastructure Partners Antin Infrastructure Partners is a leading private equity firm focused on infrastructure. With over €33 billion in assets under management across its Flagship, Mid Cap and NextGen investment strategies, Antin targets investments in the energy and environment, digital, transport and social infrastructure sectors. With offices in Paris, London, New York, Singapore, Seoul and Luxembourg, Antin employs over 240 professionals dedicated to growing, improving and transforming infrastructure businesses while delivering long-term value to portfolio companies and investors. Majority owned by its partners, Antin is listed on compartment A of the regulated market of Euronext Paris (Ticker: ANTIN – ISIN: FR0014005AL0). View source version on Contacts Media Thomas Kamm, Partner – Head of CommunicationNicolle Graugnard, Communication DirectorEmail: media@ Shareholder Relations Ludmilla Binet, Head of Shareholder RelationsEmail: shareholders@ Brunswick Email: antinip@ Tristan Roquet Montegon: +33 (0)6 37 00 52 57
